The Importance Of biomarkers In Diagnosing Managing and Predicting Diabetes
DOI:
https://doi.org/10.24237/Keywords:
Gestational diabetes, Insulin resistance , biomarker Analysis, HbA1cAbstract
Aims: Diabetes mellitus (DM) is a multifaceted metabolic disorder characterized by chronic hyperglycaemia due to impairments in insulin secretion, insulin action, or both. Traditional management approaches often fail to address the heterogeneous nature of DM, leading to suboptimal outcomes. Biomarkers have emerged as essential tools for stratifying patients and guiding personalized treatment strategies.
This study analyses selected diabetes cases and explores the role of biomarkers in designing individualized therapies. Key findings demonstrate improved glycaemic control, reduced cardiovascular risks, and enhanced patient outcomes through biomarker-guided interventions. We can conclude from this study and the results on the crucial role of medicine in the follow-up of diabetic patients.
Study design: Samples were collected from different hospitals in Diyala Governorate (Baquba Teaching Hospital- Diyala, Al-Zahraa Hospital- Shahraban and Al-Khalis Hospital- Khalis) and it took 10 months to collect samples.
Methodology: The study included 90 patients with diabetes (T1DM, T2DM, and gestational diabetes). Their ages ranged from 25 to 70 years. The male-female ratio was 38/52. The ratio of t T2DM diabetes was 47/90, T1DM diabetes 17/90, and gestational diabetes 26/90.
Results: The results show that personalized biomarker-based therapies significantly improve blood sugar control, reduce systemic inflammation, and reduce cardiovascular risk in patients with diabetes. By tailoring treatment plans based on individual profiles, physicians are able to achieve better overall outcomes, highlighting the potential of precision medicine in diabetes management.
Conclusion: The study concludes by emphasizing the critical role of personalized medicine in improving treatment efficacy, reducing side effects, and improving patient outcomes.
References
[1] H. B. Felicia, N. E. Adler, S. A. Berkowitz, M. H. Chin, T. L. Gary-Webb, A. Navas-Acien, P. L. Thornton, and D. Haire-Joshu, Social Determinants of Health and Diabetes: A Scientific Review, PubMed Central, 44(1) 258–279(2020), DOI(https://doi.org/10.2337/dci20-0053)
[2] A. Boles, R. Kandimalla and P. H. Reddy, Dynamics of diabetes and obesity: Epidemiological perspective, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1863(5), 1026-1036(2017), DOI(https://doi.org/10.1016/j.bbadis.2017.01.016)
[3] A. Antar, N. A. Ashour, M. Sharaky, M. Khattab, N. A. Ashour, R. T. Zaid, E. J. Roh, A. A. Al-Karmalawy and A. Elkamhawy, Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments, Biomedicine & Pharmacotherapy, 168, (2021), DOI(https://doi.org/10.1016/j.biopha.2023.115734)
[4] J. Raffin, P. d. Souto, A. P. Le Traon, B. Vellas, M. A. Leheudre and Y. Rolland, Sedentary behavior and the biological hallmarks of aging, Ageing Research Reviews, 83, (2023), DOI(https://doi.org/10.1016/j.arr.2022.101807)
[5] V. S. S. Nishad, D. Dongare, A. C. Pati Tripathi, T. Tripathi and P. Tripathi, Deciphering the intricacies of immune system dysfunction and its impact on diabetes mellitus: Revisiting the communication strategies to manage diabetes mellitus, Health Sciences Review, 13, (2024), DOI(https://doi.org/10.1016/j.hsr.2024.100201)
[6] X. Cheng, X. Meng, R. Chen, Z. Song, S. Li, S. Wei, H. Lv, S. Zhang, H. Tang, Y. Jiang and R. Zhang, The molecular subtypes of autoimmune diseases, Computational and Structural Biotechnology Journal, 23, 1348-1363(2024), DOI(https://doi.org/10.1016/j.csbj.2024.03.026)
[7] A. A. Choudhury, and V. Devi Rajeswari, Gestational diabetes mellitus - A metabolic and reproductive disorder, Biomedicine & Pharmacotherapy, 143, (2021), DOI(https://doi.org/10.1016/j.biopha.2021.112183)
[8] M. Puccetti, Marilena Pariano, Aurélie Schoubben, Stefano Giovagnoli and Maurizio Ricci, Biologics, theranostics, and personalized medicine in drug delivery systems, Biologics, theranostics, and personalized medicine in drug delivery systems, 201, (2024), DOI(https://doi.org/10.1016/j.phrs.2024.107086)
[9] A. S. Cruz, A. Mendes-Frias, A. I. Oliveira, L. Dias, A. R. Matos, A. Carvalho, C. Capela, J. Pedrosa, A. G. Castro and R. Silvestre, Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia, Frontiers in immunology, 12, (2021), DOI(https://doi.org/10.3389/fimmu.2021.613422)
[10] M. Ortiz-Martínez, M. González-González, AJ. Martagón, V. Hlavinka, RC. Willson and M. Rito-Palomares, Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus, Curr Diab Rep, 22(3), 95-115(2022), DOI(https://doi.org/10.1007/s11892-022-01453-4)
[11] G. E. Grieco, Z. M. Besharat, G.Licata, D. Fignani, N. Brusco, L. Nigi, C. Formichi, A. Po, C. Sabato, A. Dardano, A. Natali, F. Dotta, G. Sebastiani, and E. Ferretti, Circulating microRNAs as clinically useful biomarkers for Type 2 Diabetes Mellitus: miRNomics from bench to bedside, Translational Research, 247, 137-157(2022), DOI(https://doi.org/10.1016/j.trsl.2022.03.008)
[12] M. Jabara, O. Kose, G. Perlman, S. Corcos, and M. Ant, Artificial Intelligence-Based Digital Biomarkers for Type 2 Diabetes: A Review, Canadian Journal of Cardiology, 40(10), 1922-1933(2024), DOI(https://doi.org/10.1016/j.cjca.2024.07.028)
[13] H. Kaur, A.V. Raveendran, S. Athwal, M. Verma, V. Mutreja, K. E. Ukhurebor, and H. S. Kusuma, Assessment of diabetes biomarker monitoring via novel biosensor activity, Results in Chemistry, 5, (2023), DOI(https://doi.org/10.1016/j.rechem.2023.100777)
[14] H. Breiteneder, Y. Q. Peng, I. Agache, Z. Diamant, T. Eiwegger, W. J. Fokkens, C. Traidl-Hoffmann, K. Nadeau, R. E. O'Hehir, L. O'Mahony, O. Pfaar, M. J. Torres, D. Y. Wang, L. Zhang, and C. A. Akdis, Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma, Allergy, 75(12), 3039–3068(2020), DOI(https://doi.org/10.1111/all.14582)
[15] T. Litman, Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases, Acta pathologica microbiologica et immunologica Scandinavica, 127(5), 386-424(2019), DOI(https://doi.org/10.1111/apm.12934)
[16] C. Ciurtin, G. A. Helmy , A. C. Ferreira, J. J. Manson , E. C. Jury, and T. McDonnell, A tale of two functions: C-reactive protein complement-ary structures and, Clinical Immunology, 265(2024), DOI(https://doi.org/10.1016/j.clim.2024.110281)
[17] C. Luna-Marco, F. Iannantuoni, A. Hermo-Argibay, D. Devos, J. D. Salazar, V. M. Víctor, and S. Rovira-Llopis, Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress, Free Radical Biology and Medicine, 213, 19-35(2024), DOI(https://doi.org/10.1016/j.freeradbiomed.2024.01.015)
[18] A. Elrakaybi, K. Laubner, Q. Zhou, M. J. Hug, and J. Seufert, Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?, 64, (2022), DOI(https://doi.org/10.1016/j.molmet.2022.101549)
[19] H. Chehregosha, M. E. Khamseh, M. Malek, F. Hosseinpanah, and F. Ismail-Beigi, A View Beyond HbA1c: Role of Continuous Glucose Monitoring, Diabetes Therapy, 10, 853–863(2019), DOI(https://doi.org/10.1007/s13300-019-0619-1)
[20] J. Sztabkowska, Milena, B. Głowińska-Olszewska, and A. Bossowski, C-peptide and residual β-cell function in pediatric diabetes–state of the art, Pediatric Endocrinology Diabetes and Metabolism, 27(2), 123-133(2021), DOI(https://doi.org/10.5114/pedm.2021.107165)
[21] E. K. Duran, A. W. Aday, N. R. Cook, J. E. Buring, P. M. Ridker, and A. D. Pradhan, Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease, Journal of the American College of Cardiology, 75(17), 2122–2135(2020), DOI(https://doi.org/10.1016/j.jacc.2020.02.059)
[22] C. E. Kosmas, R. Polanco, S. Bousvarou, M. D. Papakonstantinou, E. J. Peña Genao, E. Guzman, C. E. Kostara, The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease, Diagnostics, 13(5), (2023), DOI(https://doi.org/10.3390/diagnostics13050929)
[23] A. Aulanni'am, D. K. Wuragil, H. Susanto, A. Herawati, Y. M. Nugroho, W. N.Laili Fajri, P. F. Putri, S. Susiati, J. D. T. Purnomo, A. Taufiq, and D. W. Soeatmadji, The early detection of type 1 diabetes mellitus and latent autoimmune diabetes in adults (LADA) through rapid test reverse-flow immunochromatography for glutamic acid decarboxylase 65 kDa (GAD65), Heliyon, 8(1), (2022)
[24] G. F. Hassan, and M. J. A. Al-Imari, Anti-Glutamic acid Decarboxylase Autoantibody as Biomarker for Diagnosis of Type 1DM Patients in Iraq, Indian Journal of Public Health Research & Development, 10(2), 778-783(2019)
[25] A. MMI, Role of visfatin in obesity-induced insulin resistance, World journal of clinical cases, 10(30), 10840–10851(2022), DOI(https://doi.org/10.12998/wjcc.v10.i30.10840)
[26] S. A. A. Rabo, N. A. Mohammed, S. S. Eissa, A. A. Ali, S. M. Ismail, and R. S. Gad, Serum visfatin in type 2 diabetes mellitus, Egyptian Journal of Internal Medicine, 27-32(2013), DOI(https://doi.org/10.7123/01.EJIM.0000425961.54125.23)
[27] P. Bjornstad, M. Schäfer, U. Truong, M. Cree-Green, L. Pyle , A. Baumgartner, Y. G. Reyes , A. Maniatis, S. Nayak , R. P. Wadwa, L. P. Browne, J. E. B. Reusch, and K. J. Nadeau, Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus: Randomized Controlled Trial, Circulation, 138(25), 2895-2907(2018), DOI(https://doi.org/10.1161/CIRCULATIONAHA.118.035525)
[28] Y. Chen, F. Gu, J. Guan, and Y. Ji, Metformin Might Inhibit Virus through Increasing Insulin Sensitivity, Chinese Medical Journal, 131(3), 376-377(2018), DOI(https://doi.org/10.4103/0366-6999.223856)
[29] M. Guo, J. Gu, F. Teng, J. Chen, X. Ma, Q. Chen, Y. Pu, Z. Jiang, Y. Long, and Y. Xu, The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis, Endocrine, 67, 294–304(2020), DOI(https://doi.org/10.1007/s12020-019-02175-6)
[30] E. Brown, J. P. H. Wilding, T. M. Barber, U. Alam, and D. J. Cuthbertson, Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities, Obesity Reviews, 20(6), 816-828(2019), DOI(https://doi.org/10.1111/obr.12841)
[31] C. F. Deacon, Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus, Nature Reviews Endocrinology, 16(11), 642-653(2020), DOI(https://doi.org/10.1038/s41574-020-0399-8)
[32] K. Makrilakis, The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect, International journal of environmental research and public health, 16(15), 2720(2019), DOI(https://doi.org/10.3390/ijerph16152720)
[33] G. A. Nichols, S. Philip, K. Reynolds, C. B. Granowitz, and S. Fazio, Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol, The Journal of Clinical Endocrinology & Metabolism, 103(8), 3019–3027(2018), DOI(https://doi.org/10.1210/jc.2018-00470)
[34] A. K. Shrivastava, H. V. Singh, A. Raizada, S. K. Singh, A. Pandey, N. Singh, D. S. Yadav, and H. Sharma, Inflammatory markers in patients with rheumatoid arthritis, Allergologia et Immunopathologia, 43(1), 81-87(2015), DOI(https://doi.org/10.1016/j.aller.2013.11.003)
[35] D. M.Giudice, and S. W. Gangestad, Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters, Brain, behavior, and immunity, 70(1), 61-75(2018), DOI(https://doi.org/10.1016/j.bbi.2018.02.013)
[36] A. S. Alexopoulos, A. Qamar, K. Hutchins, M. J. Crowley, B. C. Batch, and J. R. Guyton, Triglycerides: emerging targets in diabetes care? Review of moderate hypertriglyceridemia in diabetes, Current diabetes reports, 1-11(2019), DOI(https://doi.org/10.1007/s11892-019-1136-3)
[37] T. V. Rohm, D. T. Meier, J. M. Olefsky, and M. Y. Donath, Inflammation in obesity, diabetes, and related disorders, Immunity, 55(1), 31-55(2022)
[38] L. M. Jacobsen, and D. Schatz, Immunotherapy-based strategies for treatment of type 1 diabetes, Hormone Research in Paediatrics, 1-19(2024), DOI(https://doi.org/10.1159/000542002)
Downloads
Published
Issue
Section
License
Copyright (c) 2025 CC BY 4.0
This work is licensed under a Creative Commons Attribution 4.0 International License.
